Clinical trial
Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell…
NCT00062296 · Fox Chase Cancer Center, Other · Completed
Key facts
| NCT number | NCT00062296 |
|---|---|
| Title | Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia |
| Official title | Phase II Study of Epirubicin and Rituximab in Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma and CLL |
| Lead sponsor | Fox Chase Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Lymphoma |
| Intervention type | Biological, Drug |
| Interventions | rituximab, epirubicin hydrochloride |
| Enrollment | 5 |
| Start date | Mar 1, 2003 |
| Primary completion | Aug 1, 2005 |
| Completion | Aug 1, 2005 |
| First posted | Jun 6, 2003 |
| Last update posted | Jul 11, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: